Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8902116 | 0.74 | KDM4E (0.56) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL11133453 | 0.70 | BACE1 (0.41) | KDM4ELMNACYP1A2NPC1HTT | |
| SCHEMBL21895012 | 0.69 | KDM4E (0.37) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL24625410 | 0.68 | KDM4E (0.68) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL17832848 | 0.67 | KDM4E (0.59) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29351528 | 0.67 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29907716 | 0.67 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL5922 | 0.67 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL3711450 | 0.67 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL497656 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102533972-B | IL1RL-1 as a cardiovascular disease marker and therapeutic target | BRIGHAM & WOMENS HOSPITAL | 2014-07-02 | — | — | CN | disclosed |
| CN-103608066-A | Methods and devices involving non-invasive electrical nerve stimulation | HOSPITAL FOR SICK CHILDREN | 2014-02-26 | — | — | CN | disclosed |
| CN-103037829-A | Remote ischemic conditioning for treatment and prevention of restenosis | HOSPITAL FOR SICK CHILDREN | 2013-04-10 | — | — | CN | disclosed |
| CN-102939054-A | Use of remote ischemic conditioning to improve outcome after myocardial infarction | HOSPITAL FOR SICK CHILDREN | 2013-02-20 | — | — | CN | disclosed |
| CN-102533972-A | IL1RL-1 as a cardiovascular disease marker and therapeutic target | BRIGHAM & WOMENS HOSPITAL | 2012-07-04 | — | — | CN | disclosed |
| CN-1668763-B | IL1RL-1 as a marker and therapeutic target for cardiovascular disease | BRIGHAM & WOMENS HOSPITAL | 2012-05-16 | — | — | CN | disclosed |
| CN-102317786-A | Diabetes correlativity biological marker and method of application thereof | TETHYS BIOSCIENCE INC | 2012-01-11 | — | — | CN | disclosed |
| US-7964614-B2 | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090226420-A1 | Methods of Determining the Risk of Developing Coronary Artery Disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-10 | — | — | US | disclosed |
| CN-101443030-A | Use of gelsolin for diagnosis and treatment of inflammatory diseases | BRIGHAM & WOMENS HOSPITAL (US) | 2009-05-27 | — | — | CN | disclosed |
| WO-2003088811-A2 | GELSOLIN AS A PROGNOSTIC MARKER OF ARTHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| US-20030152566-A1 | Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003040691-A2 | SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2001015744-A9 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-1212101-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001015744-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-5922742-A | NOVEL COMPOUNDS ACT AS ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, AND ANALGESICS AND WOULD INHIBIT HORMONE-INDUCED UTERINE CONTRACTIONS WITHOUT MECHANISM-BASED SIDE EFFECTS | MERCK FROSST CANADA (CA) | 1999-07-13 | — | — | US | disclosed |
| US-5922742-A | NOVEL COMPOUNDS ACT AS ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, AND ANALGESICS AND WOULD INHIBIT HORMONE-INDUCED UTERINE CONTRACTIONS WITHOUT MECHANISM-BASED SIDE EFFECTS | MERCK FROSST CANADA (CA) | 1999-07-13 | — | — | US | disclosed |
| EP-0900201-A1 | PYRIDINYL-2-CYCLOPENTEN-1-ONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040012-A1 | PYRIDINYL-2-CYCLOPENTEN-1-ONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-10-30 | — | — | WO | disclosed |